BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway
Chaojin Hong1 (Research worker), Yimei Meng1 (Graduate student), Anchen Qiu1 (Graduate student), Haibo Zhang2 (Research worker), Liu Yang1 (Professor), Yupeng Hong1 (Research worker), Yumei Huang 1,* (Research worker)
1Cancer Center, Department of Medical Oncology and 2Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China
Abstract
Lung cancer is one of the most significant malignancies with both high morbidity and mortality. CDK10 is closely related to cancer progression and metastasis. However, its role in lung cancer radioresistance needs further clarification. In this study, we demonstrated that CDK10 was downregulated in lung cancer tissues, and CDK10 expression level was associated with the clinical prognosis in lung cancer patients. We also found that silencing CDK10 promoted lung cancer cell proliferation, migration and radioresistance. We further verified that silencing CDK10 facilitated the activation of JNK/c-Jun signaling, and c-Jun depletion could reverse the effects of CDK10 knockdown in lung cancer cells. Our findings revealed that CDK10 played an important role in cell growth and radioresistance by inhibiting JNK/c-Jun signaling pathway in lung cancer. Therefore, CDK10 might be a promising therapeutic target in lung cancer.
Abstract, Accepted Manuscript [Submitted on March 2, 2024, Accepted on May 30, 2024]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd